Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Clinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of sponsorship for NANORAY-312 Strengthened financial position through the closing of a non-dilutive royalty financing with HealthCare Royalty for up to $71 million and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3) Advanced the Curadigm Nanoprimer platform with four new patent applications filed, new in vivo data...

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), an energy-systems platform company that enables the safe, certifiable deployment of ultra-high-power lithium battery systems for space and defense programs, hyperscale AI data centers, and telecom infrastructure OEMs, today announced its financial results for the fourth quarter and full-year 2025. KULR CEO Michael Mo commented, “2025 marked a year of meaningful progress for KULR as we strengthened our commercial foundation and continued positioning the Company at the intersection of battery safety, performance, and next-generation energy infrastructure. We are entering 2026 with sharper strategic focus, increasing traction in priority verticals, and confidence in our ability to convert technical...

Q4 2025 Marks Transition from Restructuring to Growth For 2026, Expects Double-Digit Revenue Growth, 400% Increase in CompuFlo Sales, and Continued Progress Toward Profitability ROSELAND, N.J., March 31, 2026 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the year ended December 31, 2025. Eric Hines, Chief Executive Officer of Milestone Scientific commented: “When I joined Milestone in August 2025, we were in the middle of the third quarter following a period without consistent executive leadership. During that time, certain spending had occurred that was not always aligned with revenue generation or disciplined capital allocation. Since August,...

Full Year 2025 Revenue of $12.2 Million, up 169% from 2024  Revenue of $2.8 Million for Q4 2025, up 116% from Q4 2024 Gross Profit of $2.3 Million for Q4 2025, a 148% increase from Q4 2024; Gross Margin Expanded to 81.9% in Q4 2025, a 1,061 BPS Increase Reaches Deal to Acquire Assets of ConnectAndSell, a Profitable Company, More Than Doubling Annual Revenue and Expanding AI Platform Capabilities Management to Host Fourth Quarter and Full Year 2025 Results Conference Call Today, Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time SEATTLE, March 31, 2026 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading AI-powered sales & marketing technology company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 and Subsequent...

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) — BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it will effect a 50-for-1 share consolidation (the “Share Consolidation”) of its common stock, par value $0.0001 per share (the “Common Stock”), that is expected to become effective on April 6, 2026 at 12:01 a.m. Eastern Time (the “Effective Date”). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol “BCAB” and is expected to begin trading on a split-adjusted basis when the market opens on April 6, 2026. Following the Share Consolidation, the new CUSIP number for the Common Stock will be 09077B203. The Share Consolidation...

Geneva, Switzerland, March 31, 2026 (GLOBE NEWSWIRE) — Conference Call to be Held on April 1 at 9:00am ETAudited FY 2025 revenue of $18 million, representing 66% growth year-over-year Entered 2026 with a strong commercial momentum and expects Q1 2026 revenue to exceed $4 million and grow over 100% as compared to Q1 2025 Reaffirms FY 2026 guidance with revenue expected to grow between 50%-100% year over year Strong cash and short-term investments of over $525 million as of March 31, 2026, well positions SEALSQ to execute growth strategy Active business pipeline exceeding $200 million for 2026–2029, including over $60 million linked to QS7001 and QVault TPM programs Good progress on partnerships and investments Strategy to establish SEALSQ as a cornerstone player at the intersection of secure semiconductors, Post-Quantum cryptography,...

DALLAS, March 31, 2026 (GLOBE NEWSWIRE) — Dave & Buster’s Entertainment, Inc., (NASDAQ: PLAY), (“Dave & Buster’s” or “the Company”), an owner, operator, and franchisor of entertainment and dining venues, today announced financial results for its fourth quarter and fiscal year ended February 3, 2026. Fourth Quarter 2025 Financial SummaryRevenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024. Comparable store sales decreased 3.3% compared to the same calendar period of fiscal 2024. Excluding the impact from Winter Storm Fern in January, management estimates that fourth quarter comparable store sales would have decreased approximately 1.5%. Net loss totaled $39.8 million, or $1.15 per diluted share, compared with net income of $9.3 million, or $0.24 per diluted share in the fourth quarter of fiscal...

Sets Revenue Records in Fourth Quarter and Full Year 2025, with Revenue of $5.4 million and $14.2 million, Respectively Provides First Quarter 2026 Revenue Guidance of $5.0 to $5.2 million Representing Up to 77% Growth Compared to Prior Year Period Driven by Arps Acquisition Updates Full Year 2026 Revenue Guidance to $28 to $32 million and Full Year 2026 Adjusted EBITDA Guidance to $3.2-$3.8 million Recently Secured $7.5 million in Strategic Financing to Accelerate Manufacturing Expansion; Facility Framework Supports Over $200 million in Future Revenue Capacity LOS ANGELES, March 31, 2026 (GLOBE NEWSWIRE) — Barfresh Food Group Inc. (the “Company” or “Barfresh”) (Nasdaq: BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, today reported financial results for the fourth quarter and fiscal year ended December...

FREDERICK, Md., March 31, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, today announced financial results for the year ended December 31, 2025, and provided an update on strategic initiatives designed to drive long-term growth. 2025 Highlights:Recap of 2025: TOMI made meaningful strides across multiple strategic priorities. We continued to strengthen our government relationships, highlighted by our selection by NASA for a biosecurity operation for our reliability in mission-critical environments. Commercially, we announced several new customer wins across global CDMOs, leaders in eye health, and prestigious university research groups. In parallel, regulatory and...

DENVER, March 31, 2026 (GLOBE NEWSWIRE) — authID® (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification and authentication solutions, today reported financial and operating results for the Fourth Quarter and Fiscal Year ended December 31, 2025. Fourth Quarter 2025 vs. Fourth Quarter 2024 Financial SummaryTotal revenue for the quarter was $0.4 million, compared to $0.2 million a year ago. Operating expenses were $4.5 million, compared to $4.9 million a year ago. Net loss was $4.0 million, or $0.28 per share, compared to a loss of $4.6 million, or $0.42 per share a year ago. Adjusted EBITDA Loss of $3.0 million (non-GAAP measure as defined below), compared with $4.1 million a year ago. Gross bARR (Booked Annual Recurring Revenue) of $0.1 million (non-GAAP measure as defined below), compared...